SCHEMBL19100014

SCHEMBL19100014

CCOC(=O)c1cc(C2CC2)[nH]n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.59
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KMT2A Q03164 3/20 0.48
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CCNA1 P78396 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 3/20 0.46
MAPT P10636 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 2/20 0.45
PDE4D Q08499 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
IGF1R P08069 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387649 0.94 HCAR2 (0.61) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL4127272 0.94 HCAR2 (0.57) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL16564121 0.93 HCAR2 (0.56) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL29276120 0.83 HCAR2 (0.65) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL25139438 0.77 HCAR2 (0.71) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL1665229 0.77 DAO (0.58) HCAR2KMT2ANPSR1L3MBTL1POLB
SCHEMBL22637835 0.77 KMT2A (0.46) HCAR2KMT2ANPSR1L3MBTL1POLB
SCHEMBL18711982 0.76 HCAR2 (0.59) HCAR2NPC1RAB9AKMT2ACCNA2
SCHEMBL1423671 0.76 KMT2A (0.54) HCAR2KMT2ANPSR1L3MBTL1POLB
SCHEMBL1007015 0.76 MAPK1 (0.61) NPC1RAB9AKMT2ANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 US disclosed
CN-118638119-B Pyrazole purine herbicide safener as well as preparation method and application thereof 东北农业大学 2025-02-28 CN disclosed
CN-118638119-A Pyrazole purine herbicide safener as well as preparation method and application thereof 东北农业大学 2024-09-13 CN disclosed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 US disclosed
US-11987574-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2024-05-21 US disclosed
EP-4355733-A1 SUBSTITUTED PYRAZOLE AMIDES Grünenthal GmbH (DE) 2024-04-24 EP disclosed
EP-4313970-A1 MK2 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-02-07 EP disclosed
US-20230391795-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2023-12-07 US disclosed
CN-117120430-A MK2 inhibitors and uses thereof 新特拉有限公司 2023-11-24 CN disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 US disclosed
WO-2022263498-A1 SUBSTITUTED PYRAZOLE AMIDES Grünenthal GmbH (DE) 2022-12-22 WO disclosed
US-20220402892-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2022-12-22 US disclosed
WO-2022250069-A1 SULFUR-CONTAINING PYRAZOLE COMPOUND AND NOXIOUS ORGANISM CONTROL AGENT INCLUDING SULFUR-CONTAINING PYRAZOLE COMPOUND AS ACTIVE INGREDIENT 三井化学アグロ株式会社 2022-12-01 WO disclosed
WO-2022212489-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2022-10-06 WO disclosed
CN-114874143-A Regulator containing pyrazole derivatives, preparation method and application thereof 上海翰森生物医药科技有限公司 2022-08-09 CN disclosed
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2022-06-23 US disclosed
WO-2022094012-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-05 WO disclosed
WO-2021209552-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 WO disclosed
EP-3400223-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2018-11-14 EP disclosed
WO-2017118689-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987574-B2 MK2 inhibitors and uses thereof MKNK2, ENPP2, MAPKAPK2 HCAR2 1850/4885NPC1 3556/4885RAB9A 2972/4885
US-11999699-B2 Substituted pyrazole amides SCN8A, SCN1A, SCN7A HCAR2 565/4885NPC1 2076/4885RAB9A 1165/4885
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 HCAR2 1850/4885NPC1 3556/4885RAB9A 2972/4885
US-20220402892-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 HCAR2 1621/4885NPC1 3362/4885RAB9A 2965/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 HCAR2 76/4885NPC1 1460/4885RAB9A 2977/4885
US-20230391795-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, CRHR1 HCAR2 44/4885NPC1 627/4885RAB9A 2881/4885
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES CYP51A1, MPO, NOX5 HCAR2 2790/4885NPC1 2556/4885RAB9A 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.